Reimagining the fight against Chagas disease

Novartis (2020) C1
Chagas disease affects approximately 6 million people, mainly in Latin America. Less than 1% of affected individuals receive proper antiparasitic treatment, and current drugs are inadequate to fight the entire spectrum of the disease. Against this background, Novartis is pursuing an end-to-end approach, with activity on three fronts: drug discovery, clinical research and health system strengthening.